Edwards Lifesciences exec granted stock, options, RSUs
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP TAVR, reported equity compensation awards and related tax withholding transactions in company stock.
Rhea-AI Filing Summary
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP TAVR, reported equity compensation awards and related tax withholding transactions in company stock. He received 7,850 shares of common stock as a grant and 7,850 performance rights tied to common stock, all under the company’s Long-Term Stock Incentive Compensation Program. He was also granted 39,900 employee stock options exercisable at $82.76 per share, scheduled to vest in four equal annual installments beginning one year after the grant date. To cover tax obligations on awards vesting, 450 shares and 309 shares of common stock were withheld at prices of $82.76 and $83.20 per share, respectively. After these transactions, Lippis directly holds 40,772.9103 shares of Edwards Lifesciences common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Lippis Daniel J.
Role
CVP, TAVR
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 450 | $82.76 | $37K |
| Grant/Award | Employee Stock Option (Right to Acquire) | 39,900 | $0.00 | $0.00 |
| Grant/Award | Performance Rights | 7,850 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 7,850 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 309 | $83.20 | $26K |
Holdings After Transaction:
Employee Stock Option (Right to Acquire) — 39,900 contracts (Direct);
Performance Rights — 7,850 contracts (Direct);
Common Stock — 40,772.9103 shares (Direct)
Footnotes (3)
- F1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- F2. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- F3. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
Key Figures
Common stock grant: 7,850 shares
Performance rights target: 7,850 units
Stock options granted: 39,900 options
+5 more
8 metrics
Common stock grant
7,850 shares
Equity award of common stock granted May 7, 2026
Performance rights target
7,850 units
Target performance rights linked to common stock vesting May 7, 2029
Stock options granted
39,900 options
Employee stock options granted May 7, 2026
Option exercise price
$82.76 per share
Conversion or exercise price for 39,900 options
Tax-withheld shares
759 shares
Shares withheld to cover tax liabilities on May 7–8, 2026
Holding after transactions
40,772.9103 shares
Common stock directly held after reported Form 4 transactions
Tax withholding price 1
$82.76 per share
Price used for 450 tax-withheld shares on May 8, 2026
Tax withholding price 2
$83.20 per share
Price used for 309 tax-withheld shares on May 7, 2026
Key Terms
restricted stock units, performance rights, Long-Term Stock Incentive Compensation Program, tax-withholding disposition, +2 more
6 terms
restricted stock units financial
"These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance rights financial
"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 ... scheduled to vest on May 7, 2029."
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
Long-Term Stock Incentive Compensation Program financial
"granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
employee stock option financial
"Employee Stock Option (Right to Acquire) ... are scheduled to become vested and exercisable commencing one year after the grant date"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
performance goals financial
"The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period"
Performance goals are specific, measurable targets a company sets for financial results, operational milestones, or individual roles—examples include revenue, profit, production levels, or completion of a project. They matter to investors because meeting or missing these targets influences management pay, future forecasts, deal-related payments and market confidence; think of them as a scoreboard that helps outsiders judge whether the business is performing as promised.
FAQ
What did Daniel J. Lippis report in his latest Form 4 for Edwards Lifesciences (EW)?
Daniel J. Lippis reported new equity compensation awards and tax-related share withholdings. He received 7,850 shares of common stock, 7,850 performance rights, and 39,900 stock options, while 759 shares were withheld to satisfy tax obligations tied to vesting awards.
What equity awards did Daniel J. Lippis receive from Edwards Lifesciences (EW)?
He received 7,850 shares of common stock, 7,850 performance rights, and 39,900 employee stock options. The options have an exercise price of $82.76 per share and, along with certain restricted units, vest in four equal annual installments starting one year after the grant.
What are the terms of Daniel J. Lippis’s new stock options at Edwards Lifesciences (EW)?
Lippis was granted 39,900 employee stock options with a conversion or exercise price of $82.76 per share. These options were granted on May 7, 2026 and are scheduled to vest and become exercisable in four equal annual installments beginning one year after the grant date.
How do the performance rights granted to Daniel J. Lippis at Edwards Lifesciences (EW) work?
Lippis received 7,850 performance rights linked to an equal number of common shares. These rights are scheduled to vest on May 7, 2029, with the actual number vesting ranging from 0% to 200% of the target amount based on achievement of specified three-year performance goals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
